启东市2001-2007年肝癌生存率分析

Survival of liver cancer during 2001-2007 in Qidong city

目的:对启东2001-2007年全人群肝癌登记病例进行生存率分析,为预后评价及防治提供依据。方法:6 217例登记病例的生存(死亡)情况随访截止于2009-12-31;剔除"死亡报告"或"死亡医学证明"(DCO)病例,实际纳入分析6 104例。SURV 3.01软件计算5年观察生存率(OS)及5年相对生存率(RS)。结果:肝癌1、3和5年OS分别为18.68%、10.85%和8.94%,1、3和5年RS分别为19.11%、11.61%和10.00%。其中男性1、3和5年RS分别为19.73%、11.69%和9.84%,女性为17.24%、11.39%和10.55%,男女性生存率差异无统计学意义,P>0.05。15～34、>34～44、>44～54、>54～64、>64～74及>74岁各年龄组的5年RS分别为12.88%、8.50%、10.57%、9.20%、10.52%及13.05%。5年RS比启东1972-1981及1982-1991年时的2.2%及2.3%有较大的提高。结论:启东市全人群肝癌登记病例总体生存率有较大的提高,但与国外发达国家相比尚有差距。我国肝癌的总体治疗水平亟待提高。

OBJECTIVE： To analyze survival rates of liver cancer on the population-based cancer registry for the years 2001-2007 in Qidong in order to provide information for the prognosis assessment and the control of this disease. METHODS： The deadline of the last follow-up for survival status of the 6 217 registered cases was December 31st, 2009. DCO （death certificates only） cases were excluded, leaving 6 104 cases for survival analysis. Cumulative observed survival rate （OS） and relative survival rate （RS） were calculated using Hakulinen＇s method performed by The SURV3.01 Software developed at the Finnish Cancer Registry. RESULTS： The 1-, 3- and 5-year OS were 18.68%, 10.85%, 8.94%, and the 1-, 3- and 5-year RS were 19.11%, 11. 61%, 10.00%, respectively. The 1-, 3-, and 5-year relative survival rates of males vs females were 19.73% vs 17.24%, 11.69% vs 11.39%0, and 9.84% vs 10.55%, respectively, with no statisitically significant differences （P〉0.05）. Relative survival rates of age groups of 15-34, 〉34-44, 〉44-54, 〉54-64, 〉64- 74, and 〉74 years were 12. 88%, 8. 50%, 10. 57%, 9. 20%, 10.52% and 13.05%, respectively. Remarkable improvement could be seen for the 5-year RS in this setting if compared with that for the years 1972-1981 （RS=2. 2%）, and 1982-1991 （RS=2. 3%）. CONCLUSIONS： The survival outcomes of liver cancer in Qidong has been improved for the past decades. Yet, the disparities are there if compared to survival rates from developed countries. The technique for the treatment of liver cancer in China should be improved further.